Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Therapeutic Advances in Neurological Disorders|July 21, 2025
A systematic literature review of the association between global brain atrophy and the Expanded Disability Status Scale score in people with multiple sclerosisRobert Zivadinov, Hoa H Le, Alexander Keenan, et al.
Multiple Sclerosis and Related Disorders|July 8, 2022
Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse RateBrian Hennessy, Matthew L Zierhut, Hilke Kracker, et al.
BMC Psychiatry|March 18, 2022
Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time surveyAlexander Keenan, Dee Lin, Jason Shepherd, et al.
BMC Neurology|December 3, 2021
Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature reviewAbril Oliva Ramirez, Alexander Keenan, Olivia Kalau, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 24, 2024
Meaningful Change Thresholds and Fatigue Severity Points on Patient-Reported Outcomes by the Fatigue Symptoms and Impacts Questionnaire in Patients With Relapsing Multiple SclerosisStacie Hudgens, Eva G Katz, Evan Davies, et al.
Patient Preference and Adherence|August 6, 2020
Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference QuestionnaireClifton Blackwood, Panna Sanga, Isaac Nuamah, et al.
Patient Preference and Adherence|January 22, 2024
Shared Decision-Making in the Treatment of Multiple Sclerosis: Results of a Cross-Sectional, Real-World Survey in Europe and the United StatesAlexander Keenan, Hoa H Le, Kavita Gandhi, et al.
Neuropsychiatric Disease and Treatment|September 6, 2022
Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months InjectionsIbrahim Turkoz, Mehmet Daskiran, H Lynn Starr, et al.
Frontiers in Psychiatry|November 12, 2021
Associations Between Relapses and Psychosocial Outcomes in Patients With Schizophrenia in Real-World Settings in the United StatesDee Lin, Kruti Joshi, Alexander Keenan, et al.
BMJ Open|March 6, 2019
Ethical and social implications of using predictive modeling for Alzheimer's disease prevention: a systematic literature review protocolZuzanna Angehrn, Clementine Nordon, Andrew Turner, et al.
Pageof 2